Results 91 to 100 of about 4,142 (167)

Comparative efficacy and safety of IL-23 p19 monoclonal antibodies for plaque psoriasis: a bayesian network meta-analysis of randomized controlled trials. [PDF]

Front Immunol
Xin T, Sun S, Liu Y.
europepmc   +1 more source

Effectiveness and safety of switching biologics after secukinumab treatment failure in moderate-to-severe plaque psoriasis: a retrospective cohort study. [PDF]

Front Med (Lausanne)
Zhang Z, Zhang B, Wen Y, Hu Q, Jiang W, Zhuo J, Luo G, Wang Y.   +7 more
europepmc   +1 more source

Benefit-risk profiling of advanced therapies in moderate-to-severe ulcerative colitis: a clustered network meta-analysis. [PDF]

Front Pharmacol
Zhang X, Qian H, Yang L, Wang H, Sun G, Lin A.   +5 more
europepmc   +1 more source

Guselkumab treatment of psoriasis results in sustained reduction of systemic inflammatory biomarkers to week 48 in three phase III randomized controlled trials. [PDF]

Skin Health Dis
Kearney N, Zimmermann M, Akawung A, Kirby B.   +3 more
europepmc   +1 more source

Reply: "Entering a new GALAXI: The importance of long-term data in Crohn's disease clinical trials". [PDF]

Inflamm Bowel Dis
Afzali A, Van Rampelbergh R.
europepmc   +1 more source

Vunakizumab-induced severe ulcerative colitis during treatment of psoriatic arthritis: a case report and literature review. [PDF]

Front Immunol
Cui Y, Tian J, Ma Z.
europepmc   +1 more source

Refractory verrucous psoriasis achieving clearance with guselkumab and subsequent response to excimer therapy. [PDF]

JAAD Case Rep
Moore LC, Cockerell C, Moore AY.
europepmc   +1 more source

Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease. [PDF]

J Dermatol
Puig L, Tsai TF, Soriano ER, Bhutani T, Miller M, Kollmeier AP, Li S, Li H, Ofori S, Pawlikowski J, Adamson E, Gooderham M, Londoño Garcia A, Lebwohl M, Nash P.   +14 more
europepmc   +1 more source

IMPACT study: large real-world evaluation of guselkumab in psoriatic arthritis integrating clinical response and treatment persistence. [PDF]

Ther Adv Musculoskelet Dis
Paci V, Foti R, Pantano I, Carletto A, Celletti E, Miceli GF, Cangemi I, Lopalco G, Montalbano S, Chimenti MS, Picchianti Diamanti A, Massafra U, Filippucci E, Parisi A, Leccese P, Panaccione A, Puca I, Amato G, Marrone S, Di Penta M, Corrao S, Cela E, Rai A, Tirri E, Iannone F, Atzeni F, Rossini M, Ciccia F, Foti R, Moroncini G, Luchetti Gentiloni MM.   +30 more
europepmc   +1 more source

New Tuberculosis Infection and Reactivation of Tuberculosis in Patients with Psoriasis or Psoriatic Arthritis Receiving IL-23 Inhibitors: A Systematic Literature Review. [PDF]

Dermatol Ther (Heidelb)
Wang G, Youn SW, Chang CL, Saeki H.
europepmc   +1 more source